Skip to content

Study · Animal study (in vivo) · beagle dog · 1988

9 results

Potentiation of the gonadotoxicity of Cytoxan in the dog by adjuvant treatment with a luteinizing hormone-releasing hormone agonist.

Goodpasture JC, Bergstrom K, Vickery BH

Cancer research1 Apr 1988Cited by 12 (Europe PMC)

PMID2964898 (opens in a new tab)PepBankPUB-02964898
Publisher pageAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In dogs, adding nafarelin to cyclophosphamide prevented sperm recovery throughout 65 weeks after treatment, unlike cyclophosphamide alone.

    In plain wordsIn dogs, sperm did not recover after nafarelin plus cyclophosphamide, unlike cyclophosphamide alone.

    Peptide
    Nafarelin
    Outcome
    DecreasePersistent azoospermia with cyclophosphamide
    Study

    beagle dogn = 4

    Mature male beagle dogs
    Comparator
    Cyclophosphamide alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 48 and 52 weeksAs given in this study (beagle dog).

    Source sentences

    Summary
    The animals receiving cyclophosphamide plus nafarelin were azoospermic for the entire 65-wk PT period, and at 65 wk PT no germinal cells were found upon evaluation of testicular histology.
    2 context sentences
    Summary · context
    Sperm numbers in cyclophosphamide-only-treated animals began to rise 10-11 wk PT
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In dogs, nafarelin plus cyclophosphamide left no germinal cells at 65 weeks after treatment, unlike recovery with cyclophosphamide alone.

    In plain wordsIn dogs, no germinal cells remained after nafarelin plus cyclophosphamide, unlike largely normal sperm production after cyclophosphamide alone.

    Peptide
    Nafarelin
    Outcome
    DecreaseGerminal cell loss with cyclophosphamide
    Study

    beagle dogn = 4

    Mature male beagle dogs
    Comparator
    Cyclophosphamide alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 48 and 52 weeksAs given in this study (beagle dog).

    Source sentences

    Summary
    The animals receiving cyclophosphamide plus nafarelin were azoospermic for the entire 65-wk PT period, and at 65 wk PT no germinal cells were found upon evaluation of testicular histology.
    2 context sentences
    Summary · context
    Spermatogenesis in these cyclophosphamide-only-treated animals was normal in most seminiferous tubules at this time.
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In nafarelin-only-treated dogs, normally motile sperm appeared 6 to 8 weeks after treatment ended.

    In plain wordsIn dogs given nafarelin alone, normally moving sperm appeared 6 to 8 weeks after treatment ended.

    Peptide
    Nafarelin
    Outcome
    IncreaseMotile sperm recovery
    Study

    beagle dogn = 2

    Mature male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 48 and 52 weeksAs given in this study (beagle dog).

    Source sentences

    Summary
    Normally motile ejaculated spermatozoa were noted at 6 to 8 wk PT in nafarelin-only-treated animals; normal sperm numbers were reached at 14 wk PT.
    1 context sentence
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In nafarelin-only-treated dogs, sperm numbers reached normal levels 14 weeks after treatment ended.

    In plain wordsIn dogs given nafarelin alone, sperm numbers returned to normal 14 weeks after treatment ended.

    Peptide
    Nafarelin
    Outcome
    IncreaseSperm number recovery
    Study

    beagle dogn = 2

    Mature male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 48 and 52 weeksAs given in this study (beagle dog).

    Source sentences

    Summary
    Normally motile ejaculated spermatozoa were noted at 6 to 8 wk PT in nafarelin-only-treated animals; normal sperm numbers were reached at 14 wk PT.
    1 context sentence
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In dogs, nafarelin completely suppressed plasma testosterone before cyclophosphamide began.

    In plain wordsIn dogs, nafarelin completely suppressed testosterone before cyclophosphamide began.

    Peptide
    Nafarelin
    Outcome
    DecreaseTestosterone suppression before cyclophosphamide
    Study

    beagle dogn: not reported in source

    Mature male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 7 weeks before cyclophosphamideAs given in this study (beagle dog).

    Source sentences

    Summary
    Plasma testosterone, spermatogenesis, and ejaculate volume were completely suppressed by nafarelin prior to starting cyclophosphamide.
    2 context sentences
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)
    Summary · context
    (d) cyclophosphamide plus nafarelin [same schedule as above with cyclophosphamide (570 and 698 mg/kg total dose) starting 7 wk after beginning nafarelin]
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In dogs, nafarelin completely suppressed spermatogenesis before cyclophosphamide began.

    In plain wordsIn dogs, nafarelin completely suppressed sperm production before cyclophosphamide began.

    Peptide
    Nafarelin
    Outcome
    DecreaseSpermatogenesis before cyclophosphamide
    Study

    beagle dogn: not reported in source

    Mature male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 7 weeks before cyclophosphamideAs given in this study (beagle dog).

    Source sentences

    Summary
    Plasma testosterone, spermatogenesis, and ejaculate volume were completely suppressed by nafarelin prior to starting cyclophosphamide.
    2 context sentences
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)
    Summary · context
    (d) cyclophosphamide plus nafarelin [same schedule as above with cyclophosphamide (570 and 698 mg/kg total dose) starting 7 wk after beginning nafarelin]
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In dogs, nafarelin completely suppressed ejaculate volume before cyclophosphamide began.

    In plain wordsIn dogs, nafarelin completely suppressed ejaculate volume before cyclophosphamide began.

    Peptide
    Nafarelin
    Outcome
    DecreaseEjaculate volume before cyclophosphamide
    Study

    beagle dogn: not reported in source

    Mature male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 7 weeks before cyclophosphamideAs given in this study (beagle dog).

    Source sentences

    Summary
    Plasma testosterone, spermatogenesis, and ejaculate volume were completely suppressed by nafarelin prior to starting cyclophosphamide.
    2 context sentences
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)
    Summary · context
    (d) cyclophosphamide plus nafarelin [same schedule as above with cyclophosphamide (570 and 698 mg/kg total dose) starting 7 wk after beginning nafarelin]
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In dogs after nafarelin withdrawal, plasma testosterone reached normal levels by 2 weeks.

    In plain wordsIn dogs, testosterone returned to normal by 2 weeks after nafarelin treatment ended.

    Peptide
    Nafarelin
    Outcome
    IncreaseTestosterone recovery
    Study

    beagle dogn: not reported in source

    Mature male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 48 and 52 weeksAs given in this study (beagle dog).

    Source sentences

    Summary
    By 2 wk after cessation of treatment (posttreatment, PT), plasma testosterone reached normal levels, and at 5 wk PT ejaculates appeared which reached normal volumes 2 to 3 wk later.
    1 context sentence
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In dogs after nafarelin withdrawal, ejaculates appeared at 5 weeks and reached normal volumes 2 to 3 weeks later.

    In plain wordsIn dogs, ejaculates returned at 5 weeks after nafarelin ended and reached normal volumes 2 to 3 weeks later.

    Peptide
    Nafarelin
    Outcome
    IncreaseEjaculate recovery
    Study

    beagle dogn: not reported in source

    Mature male beagle dogs
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    2 micrograms/kg daily · subcutaneous · 48 and 52 weeksAs given in this study (beagle dog).

    Source sentences

    Summary
    By 2 wk after cessation of treatment (posttreatment, PT), plasma testosterone reached normal levels, and at 5 wk PT ejaculates appeared which reached normal volumes 2 to 3 wk later.
    1 context sentence
    Summary · context
    (c) nafarelin (2 micrograms/kg s.c. daily for 48 and 52 wk)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.